

Anti-Cancer Drugs 2005

Cumulative Contents to Volume 16

Number 1 January 2005

REVIEW PAPERS

- 1 **ZD9331: discovery to clinical development**
TS Benepal and I Judson
- 11 **Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion**
JKL Woodward, RE Coleman and I Holen

CLINICAL REPORTS

- 21 **Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial**
P Schmid, J Krocker, C-O Schulz, K Michniewicz, A Dieing, H Eggemann, V Heilmann, J-U Blohmer, O Sezer, D Elling and K Possinger
- 31 **Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer**
M Quintela-Fandino, C Gravalos, E Gonzalez, A García-Velasco and H Cortés-Funes
- 39 **Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study**
R-D Hofheinz, U Gnad-Vogt, A Wein, S Saussele, S Kreil, L Pilz, R Hehlmann and A Hochhaus
- 47 **Phase I dose escalation study of oxaliplatin combined with oral tegafur–uracil and leucovorin in patients with advanced gastric cancer**
J-S Chen, J-S Huang, T-S Yang, Y-C Lin, H-M Wang, C-T Liao and K-M Rau
- 53 **Phase II trial of vinorelbine tartrate in patients with treatment-naïve metastatic melanoma**
A Jimeno, R Hitt, M Quintela-Fandino and H Cortés-Funes
- 59 **Cytarabine-induced fever complicating the clinical course of leukemia**
C Gonen, I Celik, YS Cetinkaya and I Haznedaroglu

- 63 **Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial**
B Neri, G Cipriani, C Fulignati, M Turrini, R Ponchiatti, R Bartoletti, A Della Melina, V Di Cello, A Dominici, D Maleci, A Raugi, D Villariand and G Nicita
- 67 **Genetic effects caused by potent antileukemic steroidal esters of chlorambucil's active metabolite**
A Kouloumenta, G Stephanou, NA Demopoulos and SS Nikolaropoulos
- 67 **Genetic effects caused by potent antileukemic steroidal esters of chlorambucil's active metabolite**
A Kouloumenta, G Stephanou, NA Demopoulos and SS Nikolaropoulos
- 77 **Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer**
A Gómez-Bernal, JJ Cruz, A Olaverri, A Arizcun, T Martín, CA Rodríguez, G Martín, E Fonseca and P Sánchez

CASE REPORTS

- 83 **Precore mutant hepatitis B reactivation after treatment with CHOP–rituximab**
JA Zell, EJ Yoon, S-HI Ou, JC Hoefs and JC Chang
- 87 ***In vitro* chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer**
J Trojan, S-Z Kim, K Engels, S Kriener, PS Mitrou and KU Chow

PRECLINICAL REPORTS

- 93 **The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species**
X Wu and BB Hasinoff

- 101 Cytotoxic effects of novel polyoxotungstates and a platinum compound on human cancer cell lines**
HUV Gerth, A Rompel, B Krebs, J Boos and C Lanvers-Kaminsky

Instruction for Authors

Number 2 February 2005

REVIEW PAPERS

- 107 Ibandronate in metastatic bone disease: a review of preclinical data**
F Bauss and J-J Body
- 119 Arsenic in cancer therapy**
J Hu, J Fang, Y Dong, SJ Chen and Z Chen

PRECLINICAL REPORTS

- 129 The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines**
M Heim, M Scharifi, J Zisowsky, U Jaehde, D Voliotis, S Seeber and D Strumberg
- 137 The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzo-thiazole induces NF- κ B activity in drug-sensitive MCF-7 cells**
E Brantley, V Patel, SF Stinson, V Trapani, CD Hose, HP Ciolino, GC Yeh, JS Gutkind, EA Sausville and AI Loaiza-Pérez
- 145 Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines**
P Moreau, S Holbeck, M Prudhomme and EA Sausville
- 151 Effects of retinoic acid steroidal analogs on human leukemic HL60 cell proliferation *in vitro* and on angiogenesis *in vivo***
ES Arsenou, EP Papadimitriou, E Klifa, M Hountala and SS Nikolaropoulos
- 159 Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma**
CA Kanashiro, AV Schally, R-Z Cai and G Halmos

- 167 Enhanced cytotoxicity of bio-reductive antitumor agents with dimethyl fumarate in human glioblastoma cells**
B Gu and LM DeAngelis

- 175 Compound 278E, structurally modified from tanshinone, induces monocytic differentiation and regulates proto-oncogene expression in human leukemic HL-60 cells**
H-F Liao, S-Y Shyu, Y-H Kuo, Y-C Yang and Y-J Chen

CLINICAL REPORTS

- 185 Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience**
WJ Köstler, GG Steger, M Krainer, GV Kornek, GJ Locker, T Brodowicz, C Marosi, CF Singer, G Hudelist, W Rabitsch, C Wiltshcke and CC Zielinski
- 191 Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program**
E Razis, D Skarlos, E Briasoulis, M Dimopoulos, G Fountzilas, S Lambropoulos, S Rigatos, P Kopterides, H Efstathiou, E Tzamakou, C Bakoyannis, D Pectasides, T Makatsoris, G Varthalitis, S Papadopoulos and P Kosmidis

CASE REPORT

- 199 Long-term remission of excessive liver metastases in a breast cancer patient with chronic alcohol abuse using a monotherapy with trastuzumab**
MHR Eichbaum, A Schneeweiss and G Bastert

COMMENTARY

- 201 Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens**
M Chvapil

MEETING REPORT

- 211 New Drugs in Cancer Therapy, National Tumor Institute, Naples, 17–18 June 2004**
F Caponigro, M Basile, V de Rosa and N Normanno

Instruction for Authors

Number 3 March 2005

REVIEW PAPERS

- 223 ***In vitro* assays for anticancer drug discovery—a novel approach based on engineered mammalian cell lines**
V Gonzalez-Nicolini and M Fussenegger
- 229 **Molecular mechanisms of polyamine analogs in cancer cells**
Y Huang, A Pledgie, RA Casero Jr and NE Davidson
- 243 **Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane**
JW Singer, S Shaffer, B Baker, A Bernareggi, S Stromatt, D Nienstedt and M Besman

PRECLINICAL REPORTS

- 255 **Effect of sodium butyrate on doxorubicin resistance and expression of multidrug resistance genes in thyroid carcinoma cells**
C Massart, C Poirier, P Fergelot, O Fardel and J Gibassier
- 263 **EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism**
BK Adams, J Cai, J Armstrong, M Herold, YJ Lu, A Sun, JP Snyder, DC Liotta, DP Jones and M Shoji
- 277 ***In vitro* drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia**
A Åleskog, R Larsson, M Höglund, J Kristensen, P Nygren and E Lindhagen
- 285 **Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells**
OH Temmink, M de Bruin, EM Comijn, M Fukushima and GJ Peters
- 293 **Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells**
Y-J Chen, C-J Shieh, T-H Tsai, C-D Kuo, L-T Ho, T-Y Liu and H-F Liao
- 301 **Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia**
M Lemaire, LF Momparler, ML Bernstein, VE Marquez and RL Momparler

CLINICAL REPORTS

- 309 **Taxotere–5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells**
J-L Fischel, J-M Ferrero, P Formento, J Ciccolini, N Renée, J-L Formento and G Milano
- 317 **Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial**
PN Lara Jr, LY Law, JJ Wright, P Frankel, P Twardowski, HJ Lenz, DHM Lau, T Kawaguchi, PH Gumerlock, JH Doroshow and DR Gandara
- 323 **Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience**
R Díaz, MV Jordá, G Reynés, J Aparicio, Á Segura, R Amador, V Calderero and A Beltrán
- 331 **Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes**
ME de Jonge, ADR Huitema, SM van Dam, S Rodenhuis and JH Beijnen
- 337 **Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation**
D Oechtering, B Schiltmeyer, G Hempel, M Schwab, G Würthwein, T Mürdter, T Klingebiel, J Vormoor, B Gruhn, G Fleischack and J Boos

CASE REPORT

- 345 **Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy**
M Snoj, Z Rudolf, M Cemazar, B Jancar and G Sersa

Instruction for Authors

Number 4 April 2005

REVIEW PAPERS

- 349 **From bench to bedside for gene-directed enzyme prodrug therapy of cancer**
GU Dachs, J Tupper and GM Tozer

- 361 **Chemotherapy strategies in the treatment of small cell lung cancer**
S Popat and M O'Brien

- 373 **Hyaluronic acid butyric esters in cancer therapy**
A Speranza, C Pellizzaro and D Coradini

PRECLINICAL REPORTS

- 381 **Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction**
G Tudor, M Alley, CM Nelson, R Huang, DG Covell, P Gutierrez and EA Sausville

- 393 **High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation**
E Llagostera, V Soto-Cerrato, R Joshi, B Montaner, P Gimenez-Bonafé and R Pérez-Tomás

- 401 **Anti-angiogenic properties of plaunotol**
K Kawai, NH Tsuno, J Kitayama, Y Okaji, K Yazawa, M Asakage, H Yamashita, T Watanabe, K Takahashi and H Nagawa

- 409 **Induction of cell cycle arrest and apoptosis in human non-small cell lung cancer A549 cells by casuarinin from the bark of *Terminalia arjuna* Linn.**
P-L Kuo, Y-L Hsu, T-C Lin, J-K Chang and C-C Lin

- 417 ***In vitro* assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment**
A Cabrespine, J-O Bay, C Barthomeuf, H Curé, P Chollet and E Debiton

- 423 ***In vivo* efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations**
RY Cheung, AM Rauth and XY Wu

CLINICAL REPORTS

- 435 **Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial**
SU Gnad-Vogt, R-D Hofheinz, S Saussele, S Kreil, A Willer, F Willeke, L Pilz, R Hehlmann and A Hochhaus

- 441 **Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer**

C Wenzel, R Bartsch, GJ Locker, D Hussian, U Pluschnig, U Sevelde, MF Gnant, R Jakesz, CC Zielinski and GG Steger

- 447 **Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx**

H-M Wang, C-T Hsueh, C-S Wang, I-H Chen, C-T Liao, M-H Tsai, S-P Yeh and JT-C Chang

- 455 **Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer**

K Kaira, A Takise, K Minato, Y Iwasaki, S Ishihara, Y Takei, S Tsuchiya, R Saito, K Sato and M Mori

CASE REPORT

- 461 **Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate**
SV Labropoulos, JA Fletcher, AM Oliveira, S Papadopoulos and ED Razis

Instruction for Authors

Number 5 June 2005

REVIEW PAPERS

- 467 **A novel anti-pancreatic cancer agent, LY293111**
X-Z Ding, MS Talamonti, RH Bell Jr and TE Adrian

- 475 **Proteasome: an emerging target for cancer therapy**
I Zavrski, C Jakob, P Schmid, H Krebbel, M Kaiser, C Fleissner, M Rosche, K Possinger and O Sezer

- 483 **Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy**
SK Pal and M Pegram

PRECLINICAL REPORTS

- 495 Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors**
SJ Mercer, F Di Nicolantonio, LA Knight, FG Gabriel, PA Whitehouse, S Sharma, A Fernando, P Bhandari, SS Somers, SK Toh and IA Cree for the NHS Collaborative Research Programme on Predictive Oncology
- 501 Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice**
T Smit, JR Snyman, EW Neuse, L Bohm and CEJ van Rensburg
- 507 Induction of apoptosis and inhibition of cyclooxygenase-2 expression by *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine in human leukemia cells**
C Park, BT Choi, KI Kang, TK Kwon, J Cheong, WH Lee, ND Kim and YH Choi
- 515 11,11'-Dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity**
Y-X Zhang, Y Chen, X-N Guo, X-W Zhang, W-M Zhao, L Zhong, J Zhou, Y Xi, L-P Lin and J Ding
- 525 Predicting the chemosensitivity of ovarian and uterine cancers with the collagen gel droplet culture drug-sensitivity test**
N Nagai, K Minamikawa, K Mukai, E Hirata, M Komatsu and H Kobayashi
- 533 The patellazoles inhibit protein synthesis at nanomolar concentrations in human colon tumor cells**
AD Richardson, W Aalbersberg and CM Ireland
- 543 Growth inhibition and apoptosis induction of human melanoma cells by ω -hydroxy fatty acids**
A Abe and K Sugiyama
- 551 Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine**
Y Wu, L Yang, B Hu, J-Y Liu, J-M Su, Y Luo, Z-Y Ding, T Niu, Q Li, X-J Xie, Y-J Wen, L Tian, B Kan, Y-Q Mao and Y-Q Wei
- 559 Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of**

tamoxifen, on estrogen receptor- α expression in the rat uterus
CA Reed, AK Berndtson and KP Nephew

- 569 Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity**
ED Lynch, R Gu, C Pierce and J Kil

CLINICAL REPORTS

- 581 Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma**
AJ Schrader, A Heidenreich, A Hegele, P Olbert, CH Ohlmann, Z Varga, R von Knobloch and R Hofmann
- 587 Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy**
J-P Durand, J Alexandre, L Guillevin and F Goldwasser

Instruction for Authors

Number 6 July 2005

REVIEW PAPERS

- 593 Screening for apoptosis—classical and emerging techniques**
H Lövborg, J Gullbo and R Larsson
- 601 Targeting Stat3 in cancer therapy**
N Jing and DJ Tweardy

CLINICAL REPORTS

- 609 Predictive value of *in vitro* assessment of cytotoxic drug activity in advanced breast cancer**
K Villman, C Blomqvist, R Larsson and P Nygren
- 617 Darbepoetin α as treatment for anemia in patients receiving chemotherapy: a single-center experience**
R Bartsch, C Wenzel, U Sevela, D Hussian, U Pluschnig, GJ Locker, R Mader, CC Zielinski and GG Steger
- 621 Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric**

cancer failing both 5-fluorouracil and taxanes

SH Park, EY Choi, S-M Bang, EK Cho, JH Lee, DB Shin, WK Lee and M Chung

- 627 **No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel**
BS Kappelhoff, ADR Huitema, ATA Mairuhu, JHM Schellens and JH Beijnen

PRECLINICAL REPORTS

- 631 ***In vitro* activity of imatinib in cells from patients with adult acute lymphoblastic leukemia**
H Hallböök, G Barbany, A Åleskog, A Björnberg, R Larsson, C Sundström and E Lindhagen
- 635 **Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines**
S Wittich, H Scherf, C Xie, B Heltweg, F Dequiedt, E Verdin, C Gerhäuser and M Jung
- 645 **Cytotoxic activity of 3-nitropyrazolo [5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents**
M Coronello, G Ciciani, E Mini, G Guerrini, B Caciagli, S Selleri, A Costanzo and T Mazzei
- 653 **Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12**
P Sova, A Mistr, A Kroutil, F Zak, P Pouckova and M Zadinova
- 659 **Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes**
B Olas, B Wachowicz, I Majsterek and J Blasiak
- 667 **Addition of low-dose tumor necrosis factor- α to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats**
S Hoving, ALB Seynhaeve, ST van Tiel, AMM Eggermont and TLM ten Hagen
- 675 **Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs**
S-S Bun, S Giacometti, R Fanciullino, J Ciccolini, H Bun and C Aubert

Instruction for Authors

Number 7 August 2005

REVIEW PAPERS

- 683 **Use of high-throughput arrays for profiling differentially expressed proteins in normal and malignant tissues**
G Hudelist, CF Singer, E Kubista and K Czerwenka
- 691 **Liposomal encapsulated anti-cancer drugs**
R-D Hofheinz, SU Gnad-Vogt, U Beyer and A Hochhaus
- 709 **Novel treatment strategies in clear-cell metastatic renal cell carcinoma**
DJ van Spronsen, KJM de Weijer, PFA Mulders and PHM De Mulder

CLINICAL REPORTS

- 719 **Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer**
IA Bruce, NJ Slevin, JJ Homer, AT McGown and TH Ward
- 727 **Compatibility and stability of Imexon in infusion devices and its *in vitro* biocompatibility**
MWJ den Brok, B Nuijen, EE Challa, C Lutz, H Georg Opitz and JH Beijnen
- 733 **Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate**
S Ferrari, F Pieretti, E Verri, L Tolentinis, M Cesari, M Versari, C Zolezzi, G Lamanna and G Bacci

CASE REPORTS

- 739 **Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung**
K-H Yeh, S-H Yeh, J-P Wan, Y-C Shen and A-L Cheng
- 743 **Cytarabine-induced lung injury: case report**
P Kopterides, M Lignos, S Mentzelopoulos, A Armaganidis and V Pappa

- 747 **Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report**
HJ Stemmler, O Weigert, M Krych, SO Schoenberg, H Ostermann and W Hiddemann

PRECLINICAL REPORTS

- 751 **Identification of a novel, orally bioavailable estrogen receptor downregulator**
T Yoneya, K Taniguchi, T Tsunenari, H Saito, Y Kanbe, K Morikawa and H Yamada-Okabe
- 757 **Single intratumoral injection of long-acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice**
M Chvapil and R Dorr
- 763 **Tumor-targeted and activated bioconjugates for improved camptothecin delivery**
PV Paranjpe, S Stein and PJ Sinko
- 777 **Autophagy is the dominant type of programmed cell death in breast cancer MCF-7 cells exposed to AGS 115 and EFDAC, new sesquiterpene analogs of paclitaxel**
M Górka, WM Daniewski, B Gajkowska, E Łusakowska, MM Godlewski and T Motyl
- 789 **The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction**
P-L Kuo, Y-L Hsu, Y-C Kuo, C-H Chang and C-C Lin

Instruction for Authors

Number 8 September 2005

REVIEW PAPER

- 797 **PI3K/Akt/mTOR pathway as a target for cancer therapy**
Daniel Morgensztern and Howard L. McLeod

PRECLINICAL REPORTS

- 805 **Usnic acid: a non-genotoxic compound with anti-cancer properties**
Margareth Mayer, Mary A. O'Neill, Karen E. Murray, Nereide S. Santos-Magalhães,

Ana Maria A. Carneiro-Leão, Alastair M. Thompson and Virginia C. L. Appleyard

- 811 **Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft**
Anna Riccardi, Daniela Meco, Paolo Ubezio, Giorgio Mazzearella, Mirko Marabese, Glynn T Faircloth, José Jimeno, Maurizio D'Incalci and Riccardo Riccardi
- 817 **A novel mechanism of action of the fumagillin analog, TNP-470, in the B16F10 murine melanoma cell line**
Marcin Okrój, Wojciech Kamysz, Ewa M. Słominska, Andrzej Mysliwski and Jacek Bigda
- 825 ***In vitro* and *in vivo* suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine – platinum anti-cancer agents**
Kenneth K. W. To, Yee-Ping Ho and Steve C. F. Au-Yeung
- 837 **Vitamin K analog (compound 5) induces apoptosis in human hepatocellular carcinoma independent of the caspase pathway**
Naoyuki Enokimura, Katsuya Shiraki, Tomoyuki Kawakita, Yukiko Saitou, Hidekazu Inoue, Hiroshi Okano, Norihiko Yamamoto, Kazushi Sugimoto, Brian I. Carr and Takeshi Nakano
- 845 **Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion *in vitro***
Julia K. L. Woodward, Helen L. Neville-Webbe, Robert E. Coleman and Ingunn Holen
- 855 **Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats**
Claudia Abramjuk, Klaus Jung, Hans-Willi Krell, Rolf Juchem, Robert Peters, Kasra Taymoorian, Andrea Staack, Carsten Stephan, Joerg Schnorr, Stefan A. Loening and Michael Lein

CLINICAL REPORTS

- 863 **Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer**
Juan Morote, Salvador Esquena, Anna Orsola, Carlos Salvador, Enrique Trilla, Luis Cecchini, Carles X. Raventós, Jacques Planas, Roberto Catalán and Jaume Reventós

- 867 **Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer**

Roland Reitsamer, Florentia Peintinger, Eva Prokop and Wolfgang Hitzl

- 871 **Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC**

G. von Minckwitz, I. Chernozemsky, L. Sirakova, P. Chilingirov, R. Souchon, N. Marschner, U. Kleeberg, C. Tsekov, D. Fritze, C. Thomssen, N. Stuart, J. B. Vermorken, S. Loibl, Kh. Merkle and M. Kaufmann

- 879 **Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy**

C. Markopoulos, M. Chrissochou, A. Michailidou, E. Tzoracoleftherakis, G. Xepapadakis, J. Papadiamantis, J. Misitizis, V. Zobolas, D. Bafaloukos and H. Gogas

- 885 ***In vitro* partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender**
- Herlinde Dumez, Gunther Guetens, Gert De Boeck, Martin S. Highley, Ernst A. de Bruijn, Allan T. van Oosterom and Robert A. A. Maes

- 893 ***In vitro* partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking**
- Herlinde Dumez, Gunther Guetens, Gert De Boeck, Martin S. Highley, Ernst A. de Bruijn, Allan T. van Oosterom and Robert A. A. Maes

CASE REPORT

- 897 **Leptomeningeal carcinomatosis in relapsed non-seminoma testis: a 1-year complete remission with high-dose chemotherapy**
- N. H. A. M. Denissen, D. J. van Spronsen, T. J. Smilde and P. H. M. De Mulder

Instruction for Authors

Number 9 October 2005

REVIEW PAPERS

- 901 **Hypoxia inducible factor-1: a novel target for cancer therapy**
- Vladimir E. Belozarov and Erwin G. Van Meir
- 911 **Jasmonates—a new family of anti-cancer agents**
- Eliezer Flescher
- 917 **Taurolidine—a new drug with anti-tumor and anti-angiogenic effects**
- Christoph A. Jacobi, Charalambos Menenakos and Chris Braumann
- 923 **Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives**
- Myrna Candelaria, Lucia Taja-Chayeb, Claudia Arce-Salinas, Silvia Vidal-Millan, Alberto Serrano-Olvera and Alfonso Dueñas-Gonzalez

PRECLINICAL REPORTS

- 935 ***In-vitro* cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction**
- Esther F. A. Brandon, Irma Meijerman, Joyce S. Klijn, Dineke den Arend, Rolf W. Sparidans, Louis López Lázaro, Jos H. Beijnen and Jan H. M. Schellens
- 945 **Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma**
- Susan M. Harris, John A. Scott, Jeffrey L. Brown, Peter A. Charlton and Prakash Mistry
- 953 **Rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria treated with anti-tumor 1,4-anthracenediones**
- Yang Wang, Elisabeth M. Perchellet, Mary M. Ward, Kaiyan Lou, Duy H. Hua and Jean-Pierre H. Perchellet
- 969 **Pilot studies of the effect of zoledronic acid (Zometa®) on tumor-derived cells *ex vivo* in the ATP-based tumor chemosensitivity assay**

Louise A. Knight, Mark Conroy, Augusta Fernando, Marta Polak, Christian M. Kurbacher and Ian A. Cree

- 977 **Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria**
Carmen Blanco-Aparicio, Belen Pequeño, Victoria Moneo, Lourdes Romero, Juan F. M. Leal, Juan Velasco, Jesús Fominaya and Amancio Carnero

CLINICAL REPORTS

- 989 **SMS 201-995 enhances S-phase block induced by 5-fluorouracil in a human colorectal cancer cell line**
Dražen Massari, Zlatko Trobonjača, Daniel Rukavina and Biserka Radošević-Stašić
- 997 **A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin**
Julian R. Molina, Joel M. Reid, Charles Erlichman, Jeff A. Sloan, Alfred Furth, Stephanie L. Safgren, Chetan D. Lathia and Steven R. Alberts
- 1003 **Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m²: a phase II trial**
Emilie Thivat, Xavier Durando, Michel D'Incan, Hervé Cure, Marie-Ange Mouret-Reynier, Jean-Claude Madelmont, Pierre Souteyrand and Philippe Chollet
- 1009 **Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding**
Bernard Royer, Emmanuel Guardiola, Emmanuel Polycarpe, Guillaume Hoizey, Delphine Delroeu, Marielle Combe, Loïc Chaigneau, Emmanuel Samain, Bruno Chauffert, Bruno Heyd, Jean-Pierre Kantelip and Xavier Pivot
- 1017 **Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities**
Olivier Mir, Jérôme Alexandre, Stanislas Ropert, Delphine Amsellem-Ouazana, Thierry Flam, Philippe Beuzeboc, Marc Zerbib, Bernard Debré, Loïc Guillevin and François Goldwasser

- 1023 **Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial**
Andreas Schneeweiss, Florian Schuetz, Christian Rudlowski, Meinhard Hahn, Ilka Lauschner, Hans-Peter Sinn, Dietrich von Fournier and Christof Sohn
- 1029 **Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer**
Jeany M. Rademaker-Lakhai, Mirjam Crul, Dick Pluim, Rolf W. Sparidans, Paul Baas, Jos H. Beijnen, Nico van Zandwijk and Jan H. M. Schellens

Instruction for Authors

Number 10 November 2005

REVIEW PAPERS

- 1037 **Targeting CK2 for cancer therapy**
KA Ahmad, G Wang, J Slaton, G Unger and K Ahmed
- 1045 **Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer**
N Shukeir, S Garde, JJ Wu, C Panchal and SA Rabbani
- 1053 **Chemoinducible gene therapy**
JJ Mezhir, H Schmidt, B Yamini, NN Senzer, MC Posner, DW Kufe and RR Weichselbaum

PRECLINICAL REPORT

- 1059 **A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies**
W-Z Gu, I Joseph, Y-C Wang, D Frost, GM Sullivan, L Wang, N-H Lin, J Cohen, VS Stoll, CG Jakob, SW Muchmore, JE Harlan, T Holzman, KA Walten, US Lador, MG Anderson, P Kroeger, LE Rodriguez, KP Jarvis, D Ferguson, K Marsh, S Ng, SH Rosenberg, HL Sham and H Zhang
- 1071 **Activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl]**

titanium dichloride against tumor colony-forming units

O Oberschmidt, A-R Hanauske, F-JK Rehmann, K Strohfelddt, N Sweeney and M Tacke

- 1075 **Structure-anti-leukemic activity relationship study of B- and D-ring modified and non-modified steroidal esters of chlorambucil's active metabolite**
A Papageorgiou, AI Koutsourea, ES Arsenou, MA Fouteris, D Mourelatos and SS Nikolaropoulos

- 1083 **Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231**
M Bigioni, A Benzo, C Irrissuto, CA Maggi and C Goso

- 1091 **In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes**
G Kelter, NJ Sweeney, K Strohfelddt, H-H Fiebig and M Tacke

- 1099 **The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan**
AH Braun, K Stark, O Dirsch, RA Hilger, S Seeber and U Vanhoefer

- 1109 **Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model**
S Yurimoto, A Miyakawa, A Okuzawa, S Sakamoto, K Sakamoto, S Hosoda and T Kamano

CLINICAL REPORTS

- 1115 **Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study**
S Stier, C Koll, T Neuhaus, S Fronhoffs, R Forkert, A Tuohimaa, H Vetter and Y Ko
- 1123 **Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer**
M Tsuboi, H Kato, K Nagai, R Tsuchiya, H Wada, H Tada, Y Ichinose, M Fukuoka and H Jiang
- 1129 **Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer**
M Zwitter, V Kovac, U Smrdel, I Kocijancic, B Segedin and M Vrankar

CASE REPORTS

- 1135 **Lasting remission following multimodal treatment in a patient with metastatic breast cancer**
HJ Stemmler, H Menzel, C Salat, H Lindhofer, S Kahlert, V Heinemann and HJ Kolb
- 1139 **Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression**
K Schönegger, E Gelpi, D Prayer, K Dieckmann, C Matula, M Hassler, JA Hainfellner and C Marosi